Skip to Content

Generic Xiidra Availability

Xiidra is a brand name of lifitegrast ophthalmic, approved by the FDA in the following formulation(s):

XIIDRA (lifitegrast - solution/drops;ophthalmic)

  • Manufacturer: SHIRE DEV LLC
    Approval date: July 11, 2016
    Strength(s): 5% [RLD]

Has a generic version of Xiidra been approved?

No. There is currently no therapeutically equivalent version of Xiidra available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xiidra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Modulators of cellular adhesion
    Patent 7,314,938
    Issued: January 1, 2008
    Inventor(s): Shen; Wang & Barr; Kenneth & Oslob; Johan D. & Zhong; Min
    Assignee(s): Sunesis Pharmaceuticals, Inc.
    The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Patent expiration dates:
    • March 10, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Modulators of cellular adhesion
    Patent 7,745,460
    Issued: June 29, 2010
    Inventor(s): Shen; Wang & Barr; Kenneth & Oslob; Johan D. & Zhong; Min
    Assignee(s): SARcode Corporation
    The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Patent expiration dates:
    • November 5, 2024
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Modulators of cellular adhesion
    Patent 7,790,743
    Issued: September 7, 2010
    Inventor(s): Shen; Wang & Barr; Kenneth & Oslob; Johan D. & Zhong; Min
    Assignee(s): SARcode Corporation
    The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof; wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof; and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Patent expiration dates:
    • November 5, 2024
  • Modulators of cellular adhesion
    Patent 7,928,122
    Issued: April 19, 2011
    Inventor(s): Shen; Wang & Barr; Kenneth & Oslob; Johan D. & Zhong; Min
    Assignee(s): SARcode Corporation
    The present invention provides compounds having formula (I); and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Patent expiration dates:
    • November 5, 2024
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compositions and methods for treatment of eye disorders
    Patent 8,084,047
    Issued: December 27, 2011
    Inventor(s): Shen; Wang & Oslob; Johan D. & Barr; Kenneth & Zhong; Min
    Assignee(s): Sarcode Bioscience Inc.
    The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Patent expiration dates:
    • May 17, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compositions and methods for treatment of eye disorders
    Patent 8,168,655
    Issued: May 1, 2012
    Inventor(s): Gadek; Thomas & Burnier; John
    Assignee(s): SARcode Bioscience Inc.
    The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Patent expiration dates:
    • May 9, 2029
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent 8,367,701
    Issued: February 5, 2013
    Assignee(s): SARcode Bioscience Inc.
    Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Patent expiration dates:
    • April 15, 2029
      ✓ 
      Drug product
  • Compositions and methods for treatment of eye disorders
    Patent 8,592,450
    Issued: November 26, 2013
    Assignee(s): SARcode Bioscience Inc.
    The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Patent expiration dates:
    • May 17, 2026
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent 8,927,574
    Issued: January 6, 2015
    Assignee(s): SARcode Bioscience Inc.
    Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Patent expiration dates:
    • November 12, 2030
      ✓ 
      Drug product
  • LFA-1 inhibitor and methods of preparation and polymorph thereof
    Patent 9,085,553
    Issued: July 21, 2015
    Assignee(s): SARCODE BIOSCIENCE, INC.
    Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.
    Patent expiration dates:
    • July 25, 2033
      ✓ 
      Drug product
  • Modulators of cellular adhesion
    Patent 9,216,174
    Issued: December 22, 2015
    Assignee(s): SARCODE BIOSCIENCE INC.
    The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Patent expiration dates:
    • November 5, 2024
      ✓ 
      Drug product
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent 9,353,088
    Issued: May 31, 2016
    Assignee(s): SARcode Bioscience Inc.
    Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Patent expiration dates:
    • October 21, 2030
      ✓ 
      Drug product
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent 9,447,077
    Issued: September 20, 2016
    Assignee(s): SARcode Bioscience Inc.
    Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Patent expiration dates:
    • April 15, 2029

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 11, 2021 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide